Angiostatin's molecular mechanism: Aspects of specificity and regulation elucidated
- 10 August 2005
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 96 (2) , 242-261
Abstract
Tumor growth requires the development of new vessels that sprout from pre‐existing normal vessels in a process known as “angiogenesis” [Folkman (1971) N Engl J Med 285:1182–1186]. These new vessels arise from local capillaries, arteries, and veins in response to the release of soluble growth factors from the tumor mass, enabling these tumors to grow beyond the diffusion‐limited size of approximately 2 mm diameter. Angiostatin, a naturally occurring inhibitor of angiogenesis, was discovered based on its ability to block tumor growth in vivo by inhibiting the formation of new tumor blood vessels [O'Reilly et al. (1994a) Cold Spring Harb Symp Quant Biol 59:471–482]. Angiostatin is a proteolytically derived internal fragment of plasminogen and may contain various members of the five plasminogen “kringle” domains, depending on the exact sites of proteolysis. Different forms of angiostatin have measurably different activities, suggesting that much remains to be elucidated about angiostatin biology. A number of groups have sought to identify the native cell surface binding site(s) for angiostatin, resulting in at least five different binding sites proposed for angiostatin on the surface of endothelial cells (EC). This review will consider the data supporting all of the various reported angiostatin binding sites and will focus particular attention on the angiostatin binding protein identified by our group: F1FO ATP synthase. There have been several developments in the quest to elucidate the mechanism of action of angiostatin and the regulation of its receptor. The purpose of this review is to describe the highlights of research on the mechanism of action of angiostatin, its' interaction with ATP synthase on the EC surface, modulators of its activity, and issues that should be explored in future research related to angiostatin and other anti‐angiogenic agents.Keywords
This publication has 105 references indexed in Scilit:
- Plasmin Reduction by Phosphoglycerate Kinase Is a Thiol-independent ProcessJournal of Biological Chemistry, 2002
- Piceatannol, a Stilbene Phytochemical, Inhibits Mitochondrial F0F1-ATPase Activity by Targeting the F1 ComplexBiochemical and Biophysical Research Communications, 1999
- Kringle 5 Causes Cell Cycle Arrest and Apoptosis of Endothelial CellsBiochemical and Biophysical Research Communications, 1999
- Selective Inhibition by Kringle 5 of Human Plasminogen on Endothelial Cell Migration, an Important Process in AngiogenesisBiochemical and Biophysical Research Communications, 1998
- Suppression of Tumor Growth with Recombinant Murine AngiostatinBiochemical and Biophysical Research Communications, 1997
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Porin interaction with hexokinase and glycerol kinase: Metabolic microcompartmentation at the outer mitochondrial membraneBiochemical Medicine and Metabolic Biology, 1991
- The role of carbohydrate in the function of human plasminogen: comparison of the protein obtained from molecular cloning and expression in Escherichia coli and COS cellsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1990
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971